82 FR 19074 - Government-Owned Inventions; Availability for Licensing
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 82, Issue 78 (April 25, 2017)
National Institutes of Health
Federal Register Volume 82, Issue 78 (April 25, 2017)
| Page Range | 19074-19075 | |
| FR Document | 2017-08350 |
[Federal Register Volume 82, Number 78 (Tuesday, April 25, 2017)] [Notices] [Pages 19074-19075] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-08350] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Peter Soukas, J.D., 301-594-8730; [email protected]. Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. Live Attenuated Zika Virus Vaccine Description of Technology This application claims live attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and multivalent immunogenic compositions comprising Zika vaccines and vaccines for other flaviviruses. The chimeric Zika viruses claimed include a first nucleotide sequence encoding at least one structural protein from a Zika virus (ZIKV), a second nucleotide sequence encoding at least one nonstructural protein from a first flavivirus, and a third nucleotide sequence of a 3' untranslated region from a second flavivirus. The multivalent immunogenic compositions claimed comprise an attenuated ZIKV vaccine or an attenuated chimeric ZIKV vaccine (or their combination) together with one or more of a first attenuated virus that is immunogenic against dengue serotype 1, a second attenuated virus that is immunogenic against dengue serotype 2, a third attenuated virus that is immunogenic against dengue serotype 3, and a fourth attenuated virus that is immunogenic against dengue serotype 4. The present disclosure also claims methods of inducing immune responses, as well as preventing ZIKV and another flavivirus, e.g., dengue virus. Such a chimeric vaccine candidate may induce a humoral (antibody) and T-cell response to ZIKV, while the nonstructural proteins of dengue virus will likely induce a T-cell response. The dengue platform also contains a deletion in the TL2 stem-loop structure of the 3' untranslated region (UTR), called [Delta]30 and [Delta]30/31 attenuating mutations. The [Delta]30 deletion has proven to be one of the defining characteristics of the successful one dose dengue vaccine, which is currently in a large scale (17,000 patient) clinical trial in Brazil. This technology is available for licensing for commercial development [[Page 19075]] in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial ApplicationsDiagnostics Vaccines Competitive Advantages One-dose vaccine Ease of manufacture Can be included in multivalent flavivirus vaccines Development Stage In vivo data available (animal) Inventors: S. Whitehead (NIAID), S. Woodson (NIAID), A. Pletnev (NIAID), K. Tsetsarkin (NIAID), A. Durbin (Johns Hopkins University) Intellectual Property: HHS Reference No. E-118-2016/0, U.S. Provisional Patent Application Number 62/307,170, filed March 11, 2016, PCT Patent Application TBA filed March 11, 2017. Licensing Contact: Peter Soukas, J.D., 301-594-8730; [email protected]. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize norovirus diagnostics or vaccines. For collaboration opportunities, please contact Peter Soukas, J.D., 301-594-8730; [email protected]. Dated: April 12, 2017. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2017-08350 Filed 4-24-17; 8:45 am] BILLING CODE 4140-01-P
![19074 Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices
property such as patentable material, Scientific Review, National Institutes of FOR FURTHER INFORMATION CONTACT:
and personal information concerning Health, 6701 Rockledge Drive, Room 3141, Peter Soukas, J.D., 301–594–8730;
individuals associated with the grant Bethesda, MD 20892, 301–827–6480, weikts@ peter.soukas@nih.gov. Licensing
mail.nih.gov.
applications, the disclosure of which information and copies of the patent
would constitute a clearly unwarranted Name of Committee: Cell Biology applications listed below may be
Integrated Review Group; Development—2
invasion of personal privacy. obtained by communicating with the
Study Section.
Name of Committee: National Institute on Date: May 25–26, 2017. indicated licensing contact at the
Aging Special Emphasis Panel; AD Genetic Time: 8:00 a.m. to 3:00 p.m. Technology Transfer and Intellectual
Variants in Human Cell Biology. Agenda: To review and evaluate grant Property Office, National Institute of
Date: May 23, 2017. applications. Allergy and Infectious Diseases, 5601
Time: 12:01 p.m. to 5:00 p.m. Place: Hotel Nikko San Francisco, 222 Fishers Lane, Rockville, MD, 20852; tel.
Agenda: To review and evaluate grant Mason Street, San Francisco, CA 94102. 301–496–2644. A signed Confidential
applications. Contact Person: Rass M. Shayiq, Ph.D.,
Place: National Institute on Aging,
Disclosure Agreement will be required
Scientific Review Officer, Center for
Gateway Building, Suite 2W200, 7201 to receive copies of unpublished patent
Scientific Review, National Institutes of
Wisconsin Avenue, Bethesda, MD 20892 Health, 6701 Rockledge Drive, Room 2182, applications.
(Telephone Conference Call). MSC 7818, Bethesda, MD 20892, (301) 435– SUPPLEMENTARY INFORMATION:
Contact Person: Maurizio Grimaldi, MD, 2359, shayiqr@csr.nih.gov. Technology description follows.
Ph.D., Scientific Review Officer, National Name of Committee: Center for Scientific
Institute On Aging, National Institutes Of Live Attenuated Zika Virus Vaccine
Review Special Emphasis Panel; PAR 16–
Health, 7201 Wisconsin Avenue, Room
323: Small Research Grants for Establishing Description of Technology
2C218, Bethesda, MD 20892, 301–496–9374,
Basic Sciences Clinical Collaboration to
grimaldim2@mail.nih.gov.
Understand Structural Birth Defects. This application claims live
(Catalogue of Federal Domestic Assistance Date: May 26, 2017. attenuated Zika viruses and vaccines,
Program Nos. 93.866, Aging Research, Time: 3:00 p.m. to 5:00 p.m. attenuated chimeric Zika viruses and
National Institutes of Health, HHS) Agenda: To review and evaluate grant vaccines, and multivalent immunogenic
Dated: April 20, 2017. applications. compositions comprising Zika vaccines
Melanie J. Pantoja, Place: Hotel Nikko San Francisco, 222 and vaccines for other flaviviruses. The
Mason Street, San Francisco, CA 94102. chimeric Zika viruses claimed include a
Program Analyst, Office of Federal Advisory Contact Person: Rass M. Shayiq, Ph.D.,
Committee Policy. first nucleotide sequence encoding at
Scientific Review Officer, Center for
[FR Doc. 2017–08349 Filed 4–24–17; 8:45 am] Scientific Review, National Institutes of least one structural protein from a Zika
BILLING CODE 4140–01–P Health, 6701 Rockledge Drive, Room 2182, virus (ZIKV), a second nucleotide
MSC 7818, Bethesda, MD 20892, (301) 435– sequence encoding at least one
2359, shayiqr@csr.nih.gov. nonstructural protein from a first
DEPARTMENT OF HEALTH AND (Catalogue of Federal Domestic Assistance flavivirus, and a third nucleotide
HUMAN SERVICES Program Nos. 93.306, Comparative Medicine; sequence of a 3’ untranslated region
93.333, Clinical Research, 93.306, 93.333, from a second flavivirus. The
National Institutes of Health 93.337, 93.393–93.396, 93.837–93.844, multivalent immunogenic compositions
93.846–93.878, 93.892, 93.893, National claimed comprise an attenuated ZIKV
Center for Scientific Review; Notice of Institutes of Health, HHS)
vaccine or an attenuated chimeric ZIKV
Closed Meetings Dated: April 19, 2017. vaccine (or their combination) together
Pursuant to section 10(d) of the David Clary, with one or more of a first attenuated
Federal Advisory Committee Act, as Program Analyst, Office of Federal Advisory virus that is immunogenic against
amended (5 U.S.C. App.), notice is Committee Policy. dengue serotype 1, a second attenuated
hereby given of the following meetings. [FR Doc. 2017–08293 Filed 4–24–17; 8:45 am] virus that is immunogenic against
The meetings will be closed to the BILLING CODE 4140–01–P dengue serotype 2, a third attenuated
public in accordance with the virus that is immunogenic against
provisions set forth in sections dengue serotype 3, and a fourth
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., DEPARTMENT OF HEALTH AND attenuated virus that is immunogenic
as amended. The grant applications and HUMAN SERVICES against dengue serotype 4. The present
the discussions could disclose disclosure also claims methods of
confidential trade secrets or commercial National Institutes of Health inducing immune responses, as well as
property such as patentable material, preventing ZIKV and another flavivirus,
and personal information concerning Government-Owned Inventions; e.g., dengue virus.
individuals associated with the grant Availability for Licensing Such a chimeric vaccine candidate
applications, the disclosure of which AGENCY: National Institutes of Health, may induce a humoral (antibody) and T-
would constitute a clearly unwarranted HHS. cell response to ZIKV, while the
invasion of personal privacy. ACTION: Notice. nonstructural proteins of dengue virus
Name of Committee: Center for Scientific will likely induce a T-cell response. The
Review Special Emphasis Panel; PAR Panel: SUMMARY: The invention listed below is dengue platform also contains a deletion
Linking Provider Recommendation to owned by an agency of the U.S. in the TL2 stem-loop structure of the 3’
Government and is available for untranslated region (UTR), called D30
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Adolescent HPV Uptake.
Date: May 16, 2017. licensing to achieve expeditious and D30/31 attenuating mutations. The
Time: 12:00 p.m. to 4:00 p.m. commercialization of results of D30 deletion has proven to be one of the
Agenda: To review and evaluate grant federally-funded research and defining characteristics of the successful
applications. development. Foreign patent
Place: National Institutes of Health, 6701
one dose dengue vaccine, which is
Rockledge Drive, Bethesda, MD 20892 applications are filed on selected currently in a large scale (17,000
(Telephone Conference Call). inventions to extend market coverage patient) clinical trial in Brazil.
Contact Person: Tasmeen Weik, DRPH, for companies and may also be available This technology is available for
MPH, Scientific Review Officer, Center for for licensing. licensing for commercial development
VerDate Sep<11>2014 17:42 Apr 24, 2017 Jkt 241001 PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 E:\FR\FM\25APN1.SGM 25APN1](https://thefederalregister.org/doc/82_FR_19152/page/1.svg)
![Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices 19075
in accordance with 35 U.S.C. 209 and 37 sale on or about April 26, 2017 (MHLS have similar performance, property
CFR part 404, as well as for further 2017–1 or Loan Sale). This notice also type, geographic location, lien position
development and evaluation under a describes generally the bidding process and other characteristics. Qualified
research collaboration. for the sale and certain persons who are bidders may submit bids on one or more
ineligible to bid. pools of Mortgage Loans or may bid on
Potential Commercial Applications individual loans.
DATES: A Bidder’s Information Package
• Diagnostics (BIP) was made available on or about The Qualification Statement describes
• Vaccines March 29, 2017. Bids for the loans must the entities/individuals that may be
be submitted on the bid date, which is qualified to bid on the Mortgage Loans
Competitive Advantages
currently scheduled for April 26, 2017 if they meet certain requirements as
• One-dose vaccine between certain specified hours. HUD detailed in the Qualification Statement.
• Ease of manufacture anticipates that an award or awards will Some entities/individuals must meet
• Can be included in multivalent be made on or before May 1, 2017. additional requirements in order to be
flavivirus vaccines Closing is expected to take place qualified to bid, including but not
between May 4 and May 8, 2017. limited to:
Development Stage
ADDRESSES: To become a qualified
Any mortgagee/servicer who
• In vivo data available (animal) originated one or more of the Mortgage
bidder and receive the BIP, prospective
Inventors: S. Whitehead (NIAID), S. bidders must complete, execute, and Loans; a mortgagor or an operator, with
Woodson (NIAID), A. Pletnev (NIAID), submit a Confidentiality Agreement and respect to any HUD insured or
K. Tsetsarkin (NIAID), A. Durbin (Johns subsidized mortgage loan (excluding the
a Qualification Statement acceptable to
Hopkins University) Mortgage Loans being offered in the
HUD. Both documents will be available
Intellectual Property: HHS Reference Loan Sale) who is currently in default,
on the HUD Web site at www.hud.gov/
No. E–118–2016/0, U.S. Provisional violation, or noncompliance with one or
fhaloansales. Please fax or email as well
Patent Application Number 62/307,170, more of HUD’s requirements or business
as mail executed original documents to
filed March 11, 2016, PCT Patent agreements; a limited partner,
JS Watkins Realty Partners, LLC:
Application TBA filed March 11, 2017. JS Watkins Realty Partners, LLC, c/o nonmanaging member, investor and/or
Licensing Contact: Peter Soukas, J.D., The Debt Exchange, 33 Federal Street, shareholder who owns a 1% or less
301–594–8730; peter.soukas@nih.gov. interest in one or more of the Mortgage
10th Floor, Boston, MA 02111,
Collaborative Research Opportunity: Loans, or in the project securing one or
Attention: MHLS 2017–1 Sale
The National Institute of Allergy and more of the Mortgage Loans; and any of
Coordinator, Fax: 1–978–967–8607,
Infectious Diseases is seeking statements the aforementioned entities’/
Email: mhls2017-1@debtx.com.
of capability or interest from parties individuals’ principals, affiliates, family
FOR FURTHER INFORMATION CONTACT: John
interested in collaborative research to members, and assigns.
Lucey, Director, Asset Sales Office, Interested entities/individuals who
further develop, evaluate or Room 3136, U.S. Department of Housing
commercialize norovirus diagnostics or fall into one of these categories should
and Urban Development, 451 Seventh review the Qualification Statement to
vaccines. For collaboration Street SW., Washington, DC 20410–
opportunities, please contact Peter determine whether they may be eligible
8000; telephone 202–402–3927. to qualify to submit a bid on the
Soukas, J.D., 301–594–8730; Hearing- or speech-impaired individuals
peter.soukas@nih.gov. Mortgage Loans. Other entities/
may call 202–708–4594 (TTY). These individuals not described herein may
Dated: April 12, 2017. are not toll-free numbers. also be restricted from bidding on the
Suzanne Frisbie, SUPPLEMENTARY INFORMATION: HUD Mortgage Loans, as fully detailed in the
Deputy Director, Technology Transfer and announces its intention to sell, in MHLS Qualification Statement.
Intellectual Property Office, National Institute 2017–1, ten (10) unsubsidized mortgage
of Allergy and Infectious Diseases. loans (Mortgage Loans) consisting of The Bidding Process
[FR Doc. 2017–08350 Filed 4–24–17; 8:45 am] seven first lien healthcare notes and one The BIP describes in detail the
BILLING CODE 4140–01–P associated 2nd lien healthcare note procedure for bidding in MHLS 2017–1.
secured by six assisted living facilities The BIP also includes a standardized
located in various locations within the non-negotiable loan sale agreement
DEPARTMENT OF HOUSING AND U.S. mainland and one assisted living (Loan Sale Agreement).
URBAN DEVELOPMENT facility in St. Thomas, U.S. Virgin As part of its bid, each bidder must
Islands. Additionally, HUD intends to submit a minimum deposit of the
[Docket No. FR–6034–N–01] greater of One Hundred Thousand
sell in MHLS 2017–1 two first lien
multifamily notes secured by two Dollars ($100,000) or ten percent (10%)
Notice of HUD-Held Multifamily and
multifamily properties located in of the aggregate bid prices for all of such
Healthcare Loan Sale (MHLS 2017–1)
Fayetteville, North Carolina and Bidder’s bids. In the event the Bidder’s
AGENCY: Office of the Assistant Willimantic, Connecticut. The Mortgage aggregate bid is less than One Hundred
Secretary for Housing—Federal Housing Loans are non-performing mortgage Thousand Dollars ($100,000), the
Commissioner, HUD. loans. The listing of the Mortgage Loans minimum deposit shall be not less than
ACTION: Notice of sale of two is included in the BIP. The Mortgage fifty percent (50%) of the Bidder’s
Loans will be sold without FHA aggregate bid. HUD will evaluate the
asabaliauskas on DSK3SPTVN1PROD with NOTICES
multifamily and eight healthcare
mortgage loans. insurance and with HUD servicing bids submitted and determine the
released. HUD will offer qualified successful bid(s) in its sole and absolute
SUMMARY: This notice announces HUD’s bidders an opportunity to bid discretion. If a bidder is successful, the
intention to sell two unsubsidized competitively on the Mortgage Loans. bidder’s deposit will be non-refundable
multifamily and eight unsubsidized The Mortgage Loans will be stratified and will be applied toward the purchase
healthcare mortgage loans, without for bidding purposes into several price, with any amount beyond the
Federal Housing Administration (FHA) mortgage loan pools. Each pool will purchase price being returned to the
insurance, in a competitive, sealed bid contain Mortgage Loans that generally bidder. Deposits will be returned to
VerDate Sep<11>2014 17:42 Apr 24, 2017 Jkt 241001 PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 E:\FR\FM\25APN1.SGM 25APN1](https://thefederalregister.org/doc/82_FR_19152/page/2.svg)
Document Created: 2017-04-25 02:18:17
Document Modified: 2017-04-25 02:18:17
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Peter Soukas, J.D., 301-594-8730; [email protected] Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. | |
| FR Citation | 82 FR 19074 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR